Additional file 1 of Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy

Additional file 1: Figure S1. WDHD1 mRNA expression between tumor and normal tissues in 20 independent cohorts from the GEO database. T is short for tumor tissues, and N is short for normal tissues (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001). Figure S2. WDHD1 mRNA expression between tumor and normal tissues in additional 22 independent cohorts from the GEO database (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001). Figure S3. WDHD1 protein expression between normal and tumor tissues by the UALCAN (**** p &lt; 0.0001, ns, not statistically significant). Figure S4. The ROC curves indicate that WDHD1 has an excellent diagnostic value in the TCGA pan-cancer cohort. The true positive rate (TPR) is shown on the Y-axis and the false positive rate (FPR) is shown on the X-axis. Diagnostic accuracy increases with a larger area under the curve (AUC). Figure S5. The diagnostic value of WDHD1 was evaluated using the GEO dataset (41 independent cohorts in total) as external validation. Figure S6. The relationship between WDHD1 and disease-specific survival (DSS). (A) A DSS forest plot of the pan-cancer cohort. Tumors are arranged according to different origins of tissue (color distinction). The association between WDHD1 expression and patient DSS in KIRP (B), BLCA (C), LIHC (D), PAAD (E), LGG (F), LUAD (G), ACC (H), MESO (I), SARC (J), and SKCM (K) is analyzed using Kaplan-Meier methods. Figure S7. The relationship between WDHD1 and progression-free interval (PFI). (A) A PFI forest plot of the pan-cancer cohort. The association between WDHD1 expression and patient PFI in KICH (B), PRAD (C), BLCA (D), OV (E), PAAD (F), LIHC (G), LGG (H), GBM (I), LUAD (J), ACC (K), PCPG (L), MESO (M), and SARC (N) is analyzed using Kaplan-Meier methods. Figure S8. WDHD1 survival analysis using 26 independent cohorts from the GEO datasets. In most cases, patient with high WDHD1 expression has a significant worse prognosis. Figure S9. Survival analysis of WDHD1 from the PrognoScan database. A total of 16 independent cohorts are included in the research. Figure S10. Survival analysis of WDHD1 from the PrognoScan database. Additional 11 independent cohorts are included in the research. Figure S11. TIDE score of WDHD1 high and low expression groups in BLCA (A), LGG (B), LIHC (C), LUAD (D), and PAAD (E). * p &lt;0.05, **** p &lt; 0.0001, ns, not statistically significant. Figure S12. The potential correlation between the mutation status of WDHD1 and overall survival (OS) (A), disease-specific survival (DSS) (B), disease-free survival (DFS) (C), and progression-free survival (PFS) (D) of the TCGA PanCancer cohort.附加文件1：图S1。来自基因表达综合数据库（Gene Expression Omnibus, GEO）的20个独立队列中，肿瘤组织与正常组织的WDHD1 mRNA表达水平。其中T代表肿瘤组织，N代表正常组织（* p < 0.05，** p < 0.01，*** p < 0.001）。图S2：来自GEO数据库的另外22个独立队列中，肿瘤与正常组织的WDHD1 mRNA表达水平（* p < 0.05，** p < 0.01，*** p < 0.001）。图S3：通过UALCAN数据库分析的正常与肿瘤组织中WDHD1蛋白表达水平（**** p < 0.0001，ns，无统计学意义）。图S4：受试者工作特征曲线（Receiver Operating Characteristic, ROC）显示，WDHD1在癌症基因组图谱（The Cancer Genome Atlas, TCGA）泛癌队列中具有优异的诊断价值。Y轴表示真阳性率（True Positive Rate, TPR），X轴表示假阳性率（False Positive Rate, FPR），曲线下面积（Area Under the Curve, AUC）越大，诊断准确性越高。图S5：采用GEO数据集（共计41个独立队列）作为外部验证，评估WDHD1的诊断价值。图S6：WDHD1与疾病特异性生存期（Disease-Specific Survival, DSS）的关联。(A) 泛癌队列的DSS森林图，肿瘤按组织起源不同进行排列（以颜色区分）。采用卡普兰-迈耶（Kaplan-Meier）法分析KIRP（B）、BLCA（C）、LIHC（D）、PAAD（E）、LGG（F）、LUAD（G）、ACC（H）、MESO（I）、SARC（J）及SKCM（K）中WDHD1表达与患者DSS的关联。图S7：WDHD1与无进展间隔期（Progression-Free Interval, PFI）的关联。(A) 泛癌队列的PFI森林图，采用卡普兰-迈耶法分析KICH（B）、PRAD（C）、BLCA（D）、OV（E）、PAAD（F）、LIHC（G）、LGG（H）、GBM（I）、LUAD（J）、ACC（K）、PCPG（L）、MESO（M）及SARC（N）中WDHD1表达与患者PFI的关联。图S8：采用GEO数据集的26个独立队列进行WDHD1生存分析。在大多数情况下，WDHD1高表达的患者预后显著更差。图S9：来自PrognoScan数据库的WDHD1生存分析，本研究共纳入16个独立队列。图S10：来自PrognoScan数据库的WDHD1生存分析，本研究额外纳入11个独立队列。图S11：BLCA（A）、LGG（B）、LIHC（C）、LUAD（D）及PAAD（E）中WDHD1高、低表达组的TIDE评分（Tumor Immune Dysfunction and Exclusion, TIDE）。* p < 0.05，**** p < 0.0001，ns，无统计学意义。图S12：WDHD1的突变状态与TCGA泛癌队列的总生存期（Overall Survival, OS）(A)、疾病特异性生存期（DSS）(B)、无病生存期（Disease-Free Survival, DFS）(C)及无进展生存期（Progression-Free Survival, PFS）(D)的潜在关联。